Biotech company InflaRx from Jena has entered the NASDAQ
11/20/2017 - The listing at the US-technology stock exchange NASDAQ provide the Thuringian company InflaRx with the sum of 100 mio US$ (about 86 mio Euros) from the capital market. The money will be invested in research, clinical trials and the licensing of antibodies.
InflaRx has specialized in antibodies which are used for combating chronic and life-threatening inflammations and autoimmune diseases. The company was founded in 2007 and was supported by the Thuringian government through private equity company bm-t Beteiligungsmanagement Thüringen mbH - a subsidiary of the Thuringian Development Bank (Thüringer Aufbaubank).